Holen Sie sich die Stockscreener-App
1.23
22.64%
-0.36
Handel nachbörslich:
1.23
Schlusskurs vom Vortag:
$1.59
Offen:
$1.44
24-Stunden-Volumen:
1.52M
Relative Volume:
7.55
Marktkapitalisierung:
$9.83M
Einnahmen:
$2.85M
Nettoeinkommen (Verlust:
$93.35M
KGV:
0.0511
EPS:
24.0802
Netto-Cashflow:
$-19.47M
1W Leistung:
-21.15%
1M Leistung:
-38.50%
6M Leistung:
-56.54%
1J Leistung:
-42.25%
1-Tages-Spanne:
$1.13
$1.4445
1-Wochen-Bereich:
$1.13
$1.67
52-Wochen-Spanne:
$0.97
$3.265
Traws Pharma Inc Stock (TRAW) Company Profile
Firmenname
Traws Pharma Inc
Sektor
Branche
Telefon
267-759-3680
Adresse
12 PENNS TRAIL, NEWTOWN
Compare TRAW vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
1.23 | 12.71M | 2.85M | 93.35M | -19.47M | 24.08 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-03-01 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-05-18 | Eingeleitet | Guggenheim | Buy |
| 2018-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-17 | Herabstufung | Maxim Group | Buy → Hold |
| 2017-10-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-04-27 | Eingeleitet | Laidlaw | Buy |
| 2015-07-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Traws Pharma Inc Aktie (TRAW) Neueste Nachrichten
Traws Pharma (TRAW) Secures $60 Million Financing for Influenza Research - GuruFocus
Traws Pharma (NASDAQ: TRAW) pivots to antivirals amid TXM IND hold - Stock Titan
Traws Pharma Reports 2025 Results, Secures PIPE Financing - TipRanks
TRAWS PHARMA INC (NASDAQ:TRAW) Reports 2025 Earnings Beat Amid Dilutive $60M PIPE Financing and FDA Hold - ChartMill
TRAWS PHARMA ($TRAW) Releases Q4 2025 Earnings - Quiver Quantitative
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights - The Manila Times
Traws Pharma (NASDAQ: TRAW) raises up to $60M PIPE and funds runway into 2027 - Stock Titan
Traws Pharma, Inc. announced that it has received $10.009423 million in funding - marketscreener.com
Traws Pharma Secures Up to $60 Million PIPE Financing to Advance Influenza Drug Trial in the UK - Minichart
Traws Pharma prices $60M PIPE financing deal to fund UK flu trial - MSN
Traws Pharma secures $10M financing for influenza trial By Investing.com - Investing.com India
Traws Pharma Secures PIPE Financing for Influenza Trial - TipRanks
A $10M cash infusion aims to push Traws flu drug into a UK trial - Stock Titan
Traws Pharma (NASDAQ: TRAW) lines up $10M PIPE plus $50M in warrants - Stock Titan
Traws Pharma Delays 10-K Amid Financing Review - TipRanks
Charles Nolan Parker Net Worth (2026) - GuruFocus
hVIVO Lands Influenza Trial Deal - Vox Markets
hVIVO signs influenza human challenge trial contract with Traws Pharma - Vox Markets
Rate Hike: Should I set a stop loss on Traws Pharma Inc2026 Action & Verified Technical Trade Signals - baoquankhu1.vn
Resistance Check: Can Traws Pharma Inc stock outperform in a bear market2026 Recap & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Aug Levels: How do insiders feel about Traws Pharma IncEarnings Growth Report & Weekly Setup with ROI Potential - baoquankhu1.vn
Traws Pharma (TRAW) CFO receives new RSU and stock option grants - Stock Titan
Traws Pharma (TRAW) CFO Parker Nolan listed as insider in Form 3 - Stock Titan
Traws Pharma, Inc. Experiences Revision in Its Stock Evaluation Amid Mixed Performance Metrics - Markets Mojo
TRAW PE Ratio & Valuation, Is TRAW Overvalued - Intellectia AI
Traws Pharma Inc. (TRAW) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Traws Pharma (TRAW) delays 2025 Form 10-K, cites financing and going-concern review - Stock Titan
Traws Pharma Forms Golden Cross, Signaling Potential Bullish Breakout Ahead - Markets Mojo
Traws Pharma Inc expected to post a loss of $1.22 a shareEarnings Preview - TradingView
Published on: 2026-03-23 16:58:08 - baoquankhu1.vn
Traws Pharma (TRAW) Expected to Announce Earnings on Monday - Defense World
Aug Weekly: Whats the analyst consensus on Traws Pharma IncMarket Risk Analysis & High Win Rate Trade Tips - baoquankhu1.vn
Traws Pharma reports phase 2 COVID-19 data, flu program update - MSN
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Experimental COVID Pill Shows Edge Over Paxlovid as Traws Hits Key Milestones - MSN
Director at Traws Pharma (TRAW) receives grant of 33,435 stock options - Stock Titan
Traws Pharma (TRAW) director granted 31,258 stock options at $1.60 - Stock Titan
Traws Pharma (TRAW) director granted 33,435 stock options at $1.60 strike - Stock Titan
Traws Pharma (TRAW) awards CEO 231,336 stock options at $1.60 - Stock Titan
Traws Pharma (TRAW) awards 118,367 stock options to Chief Science Officer - Stock Titan
Traws Pharma (TRAW) COO receives grant of 96,899 stock options at $1.60 - Stock Titan
Traws Pharma (TRAW) awards 33,435 stock options to director Jack Stover - Stock Titan
Traws Pharma (TRAW) CMO awarded 108,854 stock options at $1.60 - Stock Titan
Traw Pharma director granted 33,435 stock options | TRAW SEC FilingForm 4 - Stock Titan
Will Traws Pharma Inc. (0T20) stock draw ESG focused fundsWeekly Profit Summary & High Accuracy Investment Signals - Naître et grandir
TRAW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cash per share of Traws Pharma, Inc. – FWB:0T20 - TradingView
TRAW SEC FilingsTraws Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Traws Pharma Reports Phase 2 COVID-19 Data, Flu Program Update - MyChesCo
Traws Pharma (NASDAQ:TRAW) Trading Down 11.2% – Here’s What Happened - Defense World
Insider Sell: How much upside does Traws Pharma Inc haveTrade Entry Report & Accurate Intraday Trading Signals - baoquankhu1.vn
Finanzdaten der Traws Pharma Inc-Aktie (TRAW)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):